Search results for: Determining Value
Filter search results
Can the US Afford to Ignore Cost-effectiveness Evidence?
1 March 2014
Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation of Value and Risk…
Accounting for Preference Heterogeneity in Discrete Choice Experiments
4 May 2022
…people with experience of infertility value different aspects of Assistive Reproductive Therapy (Skedgel et al., 2021). Another OHE-led study compared the preferences of adults and adolescents for different EQ-5D-Y health…
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
…at capturing the full value of gene therapies should lead to more timely access. Several countries are achieving some of the changes recommended in a previous OHE report, demonstrating examples…
Around The World in HTAs: Egypt – The Road Ahead
31 July 2023
…service prices in low- and middle-income countries (Kaló et al., 2015). Egypt is among the first countries in the region to attempt to move beyond ERP by introducing value assessment…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…lessons from the England value-based pricing (VBP) saga in which practical ways of implementing severity and societal impact adjustments to QALYs were identified but rejected; Concluded that moving from listing…
Around The World in HTAs: India – Let All Be Healthy
29 June 2023
…and quality of life, and an Indian EQ-5D value set. One of the major contributions of HTAIn has been to support AB-PMJAY in rationalising the HBPs in terms of cost,…
OHE is pleased to appoint two Senior Visiting Fellows: Professor David Parkin and Professor Lou Garrison
5 October 2016
…Evidence Generation Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers Personalised Medicine and the Value of Molecular Diagnostics Governance models for real-world evidence The Expanding Value Footprint of Oncology Treatments Lou…
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
…(2) clarity on the value proposition (improvement offer) of a novel test, (3) balancing methodological rigour with pragmatic considerations while ensuring objectivity; and (4) considering a TPP’s local relevance alongside…
Recently Published: MCDA to Elicit Stakeholders’ Preferences: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
20 December 2016
This paper uses MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and then uses these preferences to assess the value of…